Akademska digitalna zbirka SLovenije - logo
E-resources
Peer reviewed Open access
  • Tumour suppressor death-ass...
    Chou, Ting-Fang; Chuang, Ya-Ting; Hsieh, Wan-Chen; Chang, Pei-Yun; Liu, Hsin-Yu; Mo, Shu-Ting; Hsu, Tzu-Sheng; Miaw, Shi-Chuen; Chen, Ruey-Hwa; Kimchi, Adi; Lai, Ming-Zong

    Nature communications, 06/2016, Volume: 7, Issue: 1
    Journal Article

    Death-associated protein kinase (DAPK) is a tumour suppressor. Here we show that DAPK also inhibits T helper 17 (Th17) and prevents Th17-mediated pathology in a mouse model of autoimmunity. We demonstrate that DAPK specifically downregulates hypoxia-inducible factor 1α (HIF-1α). In contrast to the predominant nuclear localization of HIF-1α in many cell types, HIF-1α is located in both the cytoplasm and nucleus in T cells, allowing for a cytosolic DAPK-HIF-1α interaction. DAPK also binds prolyl hydroxylase domain protein 2 (PHD2) and increases HIF-1α-PHD2 association. DAPK thereby promotes the proline hydroxylation and proteasome degradation of HIF-1α. Consequently, DAPK deficiency leads to excess HIF-1α accumulation, enhanced IL-17 expression and exacerbated experimental autoimmune encephalomyelitis. Additional knockout of HIF-1α restores the normal differentiation of Dapk(-/-) Th17 cells and prevents experimental autoimmune encephalomyelitis development. Our results reveal a mechanism involving DAPK-mediated degradation of cytoplasmic HIF-1α, and suggest that raising DAPK levels could be used for treatment of Th17-associated inflammatory diseases.